SUTENT is indicated for the treatment of:
- Advanced renal cell carcinoma (RCC)
|
Pfizer would like to inform health care professionals of an important update to the SUTENT prescribing information (PI).
Access Dear Healthcare Professional letter
The National Comprehensive Cancer Network (NCCN) has developed guidelines to evaluate and treat cancer patients who are experiencing heightened fatigue that interferes with activities of daily living.
Access the guidelines here
|
|
Now available: Clinical Perspectives in the Treatment of mRCC. In this video, two leading experts examine several topics concerning mRCC, including:
- The evolving treatment landscape
- Clinical factors shaping treatment decisions
- Managing patients in first-line therapy
- The NCCN recommended guidelines in mRCC
Watch this videocast now
Now available: Journal of Clinical Oncology reprint on overall survival (OS) with sunitinib versus interferon alfa (IFNα) as first-line treatment of metastatic renal cell carcinoma (mRCC). Access the reprint now.
|
Reference:
1. Data on file. Pfizer Inc, New York, NY.